Salivary Gland Tumors, Histology, Molecular and Beyond-Part I

Nora Katabi M.D.





Diagnostic approach



Salivary gland neoplasm

1- Malignant vs Benign

- Invasive borders=Malignancy
- (except for nodular oncocytosis and pleomorphic adenoma)
- Well circumscribed borders=Benign (except for intracapsular CA ex PA)



- 2- Malignant: Grading
 - Low grade
 - High grade



3-Cellular composition

- Cell types:
 - Ductal, myoepithelial, oncocytic, squamous cells, glandular/mucinous cells, acinar cells (zymogen)
- One cell type
- Biphasic
 - Two cell types: ductal-myoepithelial

Benign

- <u>Two cell types (ductal and myoepithelial</u>)
- Pleomorphic adenoma
- Basal cell adenoma
- Intercalated duct adenoma
- One cell type
- Myoepithelioma
- Canalicular adenoma
- <u>Oncocytic</u>
- Warthin 's tumor
- Oncocytoma

Malignant

- One cell type
- Ductal:
 - Salivary duct carcinoma
 - Secretory carcinoma
- Myoepithelial/modified myoepithelial:
 - Myoepithelial carcinoma
 - Polymorphous adenocarcinoma
- **<u>Biphasic</u>** (ductal & myoepithelial)
 - Adenoid cystic carcinoma
 - Epithelial myoepithelial carcinoma
 - Basal cell adenocarcinoma
 - Intraductal carcinoma

- Acinic cell carcinoma
- <u>Tumor with squamous</u> <u>phenotype</u>
 - Mucoepidermoid carcinoma (squamous and glandular)
 - Hyalinizing clear cell carcinoma

4-Architecture

- Growth patterns: Cribriform, tubular, single files, papillary, microcystsic, solid
- Predominant growth pattern

5- Stroma

• Myxoid, chondromyxoid, chondroid, hyalinized, desmoplastic

6-Differential Diagnosis

7-Immunohistochemistry

- <u>Ductal</u>: Cam5.2, CK7, EMA, CD117
- <u>Myoepithelial</u>: Calponin, SMA, myosin, S100, SOX10, GFAP
- Myoepithelial/basal/squamous: P63, P40, CK5/6
- <u>S100</u>: Positive: Myoepithelial carcinoma, secretory carcinoma, polymorphous adenocarcinoma. Negative: Salivary duct carcinoma, mucoepidermoid carcinoma, hyalinizing clear cell carcinoma
- <u>SOX10</u>: Can be positive in mucoepidermoid carcinoma & acinic cell ca
- DOG1, NR4A3 (NOR1): Acinic cell carcinoma
- <u>AR</u>: Salivary duct carcinoma
- <u>Ki-67</u>: High value supports malignancy

IHC panel

Highlights tumor architecture and cellular composition

Highlights biphasic patterns

Specific panels for certain entities

Negative staining can rule out entities

8-Molecular features

Tumor	Chromosome	Molecular Alterations
Pleomorphic adenoma Carcinoma ex PA	8q12 12q13-15	PLAG1 fusion HMGA2 fusion
Basal cell adenoma membranous variant	16q12.1	CYLD LOH/mutation
Basal cell adenoma and Basal cell adenocarcinoma, tubulotrabecullar variant	3p22	CTTNB1 mutation
Mucoepidermoid carcinoma	t(11;19) t(11;15)	CRTC1-MAML2 CRTC3-MAML2
Adenoid cystic carcinoma	6q22-23 including t(6;9) MYB-NFIB 8q13 translocation 9q34	MYB fusion MYBL1 fusion NOTCH1 mutation
Secretory carcinoma	t(12;15)	ETV6-NTRK3 ETV6-X
Clear cell carcinoma	t(12;22)	EWSR1-ATF1
Acinic cell carcinoma	t(4;9), t(9;12), t(8;9),t(2;4)	NR4A3, NR4A2
Epithelial-myoepithelial carcinoma	11p15	HRAS mutation
Polymorphous adenocarcinoma and cribriform adenocarcinoma of salivary gland	14q12 PRKD1 9q13 PRKD2 2p21 PRKD3	PRKD1 mutation PRKD1, PRKD2, PRKD3 rearrangement
Salivary duct carcinoma	17q21.1 Xq12 3q26	ERBB2 amplification AR copy gain PIK3CA mutation
Intraductal carcinoma	10q11.2 12p12.1 and 3q26	RET fusion KRAS or PIK3CA mutation
Microcystic adenocarcinoma	t(5q14.3) (18q11.2	MEF2C-SS18 fusion



Palate mass

Malignant



Cytomorphology Cellular composition



Architecture/stroma



Immunohistochemistry



- <u>Negative</u>:
 - P63, p40, calponin, SMA, AR



- <u>Positive</u>
 - BRST-2 (focal)
 - Mammaglobin
 - DOG1 (focal)

FISH- ETV6::NTRK3

Secretory Carcinoma

Salivary gland biopsy

- Limitations
 - Small samples
 - The borders cannot be assessed
 - Cannot tell benign from low grade malignancy
- Typical histology of a specific entity



Typical Pleomorphic adenoma







Salivary gland biopsy

- Malignant
 - Infiltration (sometimes)
 - High grade cytology
- Cellular composition/cell types and architecture/stroma
- Broad differential diagnosis
- IHC panel
- Molecular testing





34 YO male Biopsy from the oropharynx

Infiltrative=Malignar

Keratinization

Squamous cells





Focal mucin

Differential Diagnosis

- •Squamous cell carcinoma
- Adenosquamous carcinoma
- •Hyalinizing clear cell carcinoma
- Mucoepidermoid carcinoma

• <u>IHC</u>

- •Positive for p63/CK5/6
- •Negative for p16, S100 and myoepithelial stains

FISH:

MAML2 rearrangements

Mucoepidermoid carcinoma



Salivary gland biopsy No definite diagnosis

- 1-HG carcinoma
- 2-Low grade salivary gland neoplasm (Benign/pleomorphic adenoma and low-grade carcinomas)
- Differential diagnosis

Neck biopsy

Ductal and myoepithelial cells





No high grade features

Immunohistochemistry

СК7

Calponin



Low grade salivary gland neoplasm with ductal and myoepithelial features

D.D: Pleomorphic adenoma, basal cell adenoma, basal cell adenocarcinoma, and epithelial myoepithelial carcinoma



Pleomorphic adenoma

Myoepithelial carcinoma

Carcinoma ex pleomorphic adenoma

Salivary duct carcinoma

Pleomorphic adenoma (PA)

- Most common salivary gland tumor
- Parotid 80%, submandibular 10%, minor salivary gland 10%
- Slow growing mass, usually solitary
- Exposure to radiation increases the incidence

PA-Histology

- Encapsulated with variable encapsulation
- Composed of 3 elements:
 - Epithelial/ductal cells
 - Myoepithelial cells
 - Mesenchymal or stromal



PA-Stroma



PA-Architectural pleomorphism


PA-Mixed type of cells

• Squamous cells with keratin, mucocytes, adipocytes, acinar cells, oncocytes



PA-Peripheral irregularity



Recurrent PA

- Recurrence rate 3.4%
- Malignant transformation <1%





Clinicopathologic Characteristics and Prognostic Factors of Primary and Recurrent Pleomorphic Adenoma A Single Institution Retrospective Study of 705 Cases

Bayan Alzumaili, MD,* Bin Xu, MD, PhD,† Maelle Saliba, MD,‡ Abderhman Abuhashem, AB,§ Ian Ganly, MD,|| Ronald Ghossein, MD,† and Nora Katabi, MD†

PA-Prognostic factors

- Young age
- High mitotic activity
- Specimen integrity

Clinical case

- 46-year-old who presented with lower back pain
- Seen by a physician who requested an MRI
- Referred to MSK
- Image-guided biopsy



Biopsy from sacrum





Diagnosis

Spindle and epithelioid neoplasm with myxoid features, favor a myoepithelial neoplasm

Three years ago, patient had removal of a parapharyngeal "pleomorphic adenoma"







Proliferations of myoepithelial cells with nodular and expansile pattern







Myoepithelial carcinoma ex pleomorphic adenoma

with metastasis to bone

Myoepithelial carcinoma

Histologically challenging entity that is difficult to recognize

Can closely mimic pleomorphic adenoma

Misinterpreted Myoepithelial Carcinoma of Salivary Gland A Challenging and Potentially Significant Pitfall

Bin Xu, Wadad Mneimneh, Dianne E Torrence, Kevin Higgins, David Klimstra, Ronald Ghossein, Nora Katabi American Journal of Surgical Pathology, Februrary 15 2019

- 21 histologically challenging myoepithelial carcinomas:
 - 16 CA ex PA (most are intracapsular and minimally invasive)
 - 5 de novo myoepithelial carcinomas
- 18 cases (86%) had an initial diagnosis of benign
- 16 patients with FU: 14 (87.5%) progressed
 - 10 with local recurrences and 5 with distant metastases: lung, bone and skin
 - 2 patients died, one had an initial diagnosis of PA

Myoepithelial carcinoma

- <2% of all salivary gland carcinomas
- Under recognized entity
- De novo or CA ex PA
- Second most common histology of CA ex PA
- Parotid 75%
- Diverse clinical behavior

Myoepithelial carcinoma-Histology

- Composed almost exclusively of myoepithelial cells
- Variety of cells types
- Variety of architectural patterns





Architectural patterns









Malignancy

High grade features

- Mitotic activity
- Necrosis
- Cytologic atypia

Malignancy??? Tumor cells with bland cytology



Malignancy=Invasion

Tumor invasive pattern

Invasive patterns

Infiltrative

Nodular



Misinterpreted Myoepithelial Carcinoma of Salivary Gland A Challenging and Potentially Significant Pitfall

Bin Xu, Wadad Mneimneh, Dianne E Torrence, Kevin Higgins, David Klimstra, Ronald Ghossein, Nora Katabi American Journal of Surgical Pathology, Februrary 15 2019

Histologic features that are helpful to recognize malignancy

1- Uniformly cellular lobulated myoepithelial proliferation with pushing nodular pattern



2- Alternating hypocellular and hypercellular zonal cellular distribution



Multinodular with lobulated borders



Cellular pleomorphic adenoma



Pleomorphic adenoma



Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands: A Clinicopathologic Study of 48 Cases

Kong M, Drill EN, Morris L, Klimstra D, Gonen M, Ghossein R, Katabi N American Journal of Surgical Pathology 2015

- 48 (22 de novo and 26 CA ex PA) (FU: 44 months)
 - 10% had LN metastasis
 - 20% had local recurrences
 - 27% had distant metastases (most common lung)
- Myoepithelial carcinoma is a relatively aggressive tumor that is associated with a high rate of distant metastasis
- The presence of CA ex PA, necrosis, and vascular invasion correlated significantly with DFS
- Necrosis should be used to identify high grade myoepithelial carcinoma

Myoepithelial carcinoma-IHC A keratin and at least a myoepithelial marker



Myoepithelial carcinoma Panel of Immunohistochemistry

- Keratin (100%)
- S100 (89%)
- Calponin (76%)
- P63 (87.5%)
- SMA (64%)

Kong et al, AJSP, 2015



Molecular features

- 53% PLAG1 translocations
- *HMGA2* translocations
- *EWSR1-ATF1* fusion gene
- High number of CNAs more common in myoepithelial CA ex PA and associated with poor survival

Carcinoma ex Pleomorphic Adenoma (CA ex PA)

Carcinoma ex pleomorphic adenoma (CA ex PA)

- Carcinoma that arises in association with a pleomorphic adenoma (PA)
- Long standing mass with recent rapid growth
- 12% of salivary gland malignancies
- 6.2% of PA
- Most common = parotid
- 12% recurrent PA
- Patients are 60-70 years old

CA ex PA Histologically


PA component



PA component



PA component is intermixed with carcinoma component

CA ex PA-Prognosis

- Extent of invasion of carcinoma beyond PA capsule
- Histologic type of carcinoma



CA ex PA-Extent of invasion

- Intracapsular=malignant cytology with no extension beyond tumor capsule
- Minimally invasive (<4-6 mm)
- Invasive



Myoepithelial carcinoma ex PA

Significant risk of distant & local recurrence even when it is intracapsular or minimally invasive!







Molecular features

- <u>CA ex PA</u>
 - Rearrangements of *PLAG1* (Pleomorphic Adenoma Gene1) on 8q12 are the most gene in PA and CA ex-PA
 - Rearrangements of *HMGA2* on 12q14-15 is less frequent



PLAG1 immunohistochemical stain

• High sensitivity in PA

- Less sensitive in myoepithelial CA ex PA
 - De novo myoepithelial carcinoma negative for FISH but positive for PLAG1IHC
- Positive in other salivary gland tumors: polymorphous adenocarcinoma, basal cell adenoma/adenocarcinoma and adenoid cystic carcinoma





CA ex PA-Histologic subtypes

- Salivary duct carcinoma
- Myoepithelial carcinoma
- Epithelial myoepithelial carcinoma
- Adenocarcinoma NOS
- Carcinosarcoma

Salivary duct carcinoma (SDC)



Salivary duct carcinoma

- 10% of salivary malignancies
- Male/female: 4/1
- Patients are older than 50 years
- Parotid most common site
- Aggressive, stage III or IV, PNI: 60%, LVI: 31%, positive lymph nodes: 59%, 33% local recurrence and 46% distant metastasis
- 55-65% death within 5 years

SDC-Histology

- High grade
- Resembles mammary carcinoma
- Ductal differentiation with apocrine features
- Squamous features, sarcomatoid, micropapillary mucin rich, oncocytic

SDC-Histology





SDC-Apocrine features

SDC-IHC

- Positive:
 - CK7, GATA3, AR (>90%), Her2 (3+, 30%)
- Negative:
 - S100, SOX10, ER, PR, P63/P40



SDC-Molecular features

- AR copy number gain and splice variants
- TP53 mutation 55%
- HRAS mutations 23%
- PIK3CA mutations 23%
- ERBB2 (HER2) amplifications 35%
- PTEN deletion and BRAF mutations
- PLAG1 and HMGA2 rearrangement when it is CA ex PA

SDC-Differential diagnosis

- Apocrine carcinoma of skin adnexa/breast
- Squamous cell carcinoma
- Mucoepidermoid carcinoma
- Oncocytic carcinoma
- Salivary carcinoma NOS

SDC versus squamous cell carcinoma



SDC versus HG mucoepidermoid carcinoma





